Exchange: NASDAQ·Updated 05:06 PM EST
CELZ logo

CELZ Creative Medical Technology Holdings Inc

$0.4014
$0.0375
(8.52%)
Today
Closed $0.4025
$0.0011
(0.27%)
After Hours
Mkt Cap$3.34M
Vol75,111.00

About CELZ

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded by Timothy Warbington on December 3, 1998 and is headquartered in Phoenix, AZ.
50

Neutral Sentiment

How do you feel about CELZ?

CreativeMedical_IR
$CELZ has built intellectual property across multiple areas of its regenerative medicine and immunotherapy portfolio, creating protection around technologies being developed across different programs and indications. For a clinical-stage company, that IP can do more than protect innovation. It can support multiple paths forward-from advancing programs internally to potential licensing, partnerships, and other strategic opportunities. Technology → Intellectual Property → Multiple Paths to Potential Value That means the CELZ story isn’t tied to a single program or a single development path. As its technologies advance, the IP behind them can help expand the ways those assets may create value over time.
2
3
CreativeMedical_IR
Not all regenerative approaches to chronic lower back pain target the same stage of disease — or use the same delivery approach. Olastrocel is being developed for patients with degenerative disc disease and is administered through an ultrasound-guided intramuscular injection, rather than being injected directly into the spinal disc. That distinction matters: $CELZ is evaluating an approach designed to address the condition without requiring intradiscal administration. As Olastrocel moves through follow-up and data maturation, its differentiated clinical approach remains a key part of the program’s development story. Different approach. Different delivery. A clinical program is moving toward its next stage. $CELZ
1
4
CreativeMedical_IR
ImmCelz® is more than a name in the $CELZ pipeline. The Company continues R&D work around the platform, including laboratory research focused on validating its core technology and potential for scalable production. And in February 2026, “etaroleucel” was approved as the International Nonproprietary Name associated with CELZ-101 and the ImmCelz® cellular immunotherapy platform. Platform → Development Work → WHO INN Milestone Following CELZ beyond Olastrocel, ImmCelz® represents another proprietary platform with development work continuing behind it.
1
2
FroNOBaggins
$CELZ Long-term shareholders have understood the breadth of CELZ-201's potential for years. That isn't the issue. The issue is execution and capital allocation. Shareholders have watched the stock lose roughly 99% of its value, endured reverse splits and substantial dilution, while senior executives/directors have received millions in compensation and company capital has been directed into unrelated investments and related-party ventures. Meanwhile, Olastrocel is supposedly the lead asset approaching Phase 3, yet shareholders still have no meaningful Phase 3 budget, financing plan, regulatory roadmap or clear explanation of what capital will be required to get there. “One cell platform. Multiple development paths” sounds attractive. But CELZ does not suffer from a shortage of possibilities. It suffers from a shortage of accountability, prioritization and clearly communicated execution plans.
1
2
FroNOBaggins
$CELZ The BioDefense situation looks even worse in light of the Nov. 10 proxy. In January, CELZ called BioDefense wholly owned. By September, CEO Warbington's private company, CAC, somehow owned 40%. Where was that transaction announced, explained, valued, or approved? CELZ then paid CAC $200K PLUS 1 MILLION newly issued CELZ shares to reacquire half that stake. Consider what happened: CELZ, led by Warbington, issued shares to Warbington's own company in a related-party transaction whose underlying ownership history remains unexplained. Shareholders were diluted, while Warbington gained control of 1 MILLION additional votes (13.2%). Those votes can now help reelect the directors overseeing these transactions and approve executive compensation and the proposed evergreen equity plan. Were CELZ's conflict-of-interest policies followed? Was shareholder approval required under Nasdaq Rule 5635(a)(2)? How is this acceptable corporate governance?
4
FroNOBaggins
$CELZ IR, an IP portfolio means little without accountability for shareholder value. In January, CELZ called BioDefense wholly owned. By September, Warbington's company held 40%. CELZ then paid that company $200K PLUS 1 MILLION CELZ shares to buy back half its stake. How did it acquire 40%? What did it contribute? Who independently approved this deal? Meanwhile, CELZ funded speculative investments through Bionance, whose management entity, owned by Warbington, Dickerson and Patel, is entitled to 30% of distributions after invested capital is returned. Olastrocel still needs major development funding. Shareholders face continuing dilution while Warbington received $732,720 in 2025 compensation and CEO-controlled entities benefit from related-party deals. Are other shareholders tired of being treated like ATMs, absorbing most of the financial risk while management collects substantial compensation and insiders benefit from these arrangements? Where is the Board's accountability?
4
Kjstock
$CELZ They just dropped a new DEF 14A with the new compensation for 2027 and voting all in a new meeting coming up for you to vote!
3
SWEEN24
$CELZ added sown to .60. Trendline touch for 3rd time. Lose .58 and im out. This should be shakeout before breakout. Or management can keep posting news and not demanding about it. It's their call at this point
2
ReturnOfEsquire
$CELZ Every stock that I've seen where management/IR engages retail investors on social media ends up at or near zero...just saying.
1
TradersTrader
$CELZ Why did CELZ pay Amit N. Patel $5,000,000 in cash?? And what did that $ payment yield for CELZ shareholders? He didn’t even issue CELZ a license for use of JadiCell. I don’t get it. Patel licensed exclusive use for Lung and Brain to TSOI for $3.4 million (technically $300K Brain and $15M in TSOI stock initially in 2021) but $5 million gets CELZ….what exactly?? As a former CELZ investor, I was SHOCKED to see Dr. Ricordi brought on board as PI. Why? He’s incompetent at best. Regards.
ReturnOfEsquire
$CELZ Down 55% since the company resorted to these tactics. Totally predictable, and it suggests to me that this company is close to failure.
ReturnOfEsquire
$CELZ My last microcap (ARDS) that made a strong retail investment push went dark. Fortunately, I read between the lines and escaped with about 25% of my investment.

Advertisement|Remove ads.